Patent attributes
The present invention features modified Mycobacterium tuberculosis strains which lack a functional lspA gene, and vaccine formulations comprising the same. In many embodiments, a modified Mycobacterium tuberculosis strain of the invention comprises deletion or inactivation of the lspA gene and/or one or more non-lspA genes that are involved in Mycobacterium tuberculosis inhibition of macrophage responses to IFNγ. The present invention also features methods of using the modified Mycobacterium tuberculosis strains to treat or present Mycobacterium tuberculosis infection in mammals. In addition, the present invention features methods of using ΔlspA strains to identify non-lspA genes or other cellular components that are involved in Mycobacterium tuberculosis proinflammatory stimulation of macrophages or inhibition of macrophage responses to IFNγ.
